Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery
- 2 April 2010
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 143 (1), 38-44
- https://doi.org/10.1016/j.jconrel.2009.12.021
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Delivery of Encapsulated Doxorubicin by Ultrasound-Mediated Size Reduction of Drug-Loaded Polymer Contrast AgentsIEEE Transactions on Biomedical Engineering, 2010
- Effect of shell type on the in vivo backscatter from polymer-encapsulated microbubblesJapanese Journal of Clinical Oncology, 2004
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Development of a novel method for synthesis of a polymeric ultrasound contrast agentJournal of Biomedical Materials Research Part A, 2003
- Therapeutic applications of microbubblesEuropean Journal of Radiology, 2002
- Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcomaEuropean Journal of Cancer, 2001
- Doxorubicin-Induced CardiomyopathyThe New England Journal of Medicine, 1998
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of Clinical Oncology, 1997
- Unbedenklichkeitsaspekte bei der Anwendung von pegyliertem liposomalem Doxorubicin bei KrebspatientenDrugs, 1997
- Controlled drug release by ultrasound irradiation.CHEMICAL & PHARMACEUTICAL BULLETIN, 1985